花旗发表研报指，康方生物(09926.HK) 2024年产品销售收入为20亿元人民币(下同)，按年增长25%，净亏损录5.15亿元，展望今年卡度尼利单抗及依沃西单抗获纳入国家医保药品目录后可快速放量，将推动商业化进程，加上依沃西单抗关键数据披露，预期今年销售增长将加快。花旗将康方生物今明两年销售预测下调8%及2%，今年每股亏损预测从0.16元调整为每股亏损0.24元，明年每股盈利预测亦从0.72元下调至每股盈利0.59元。
计及依沃西单抗新适应症销量预测，该行将康方生物目标价从87港元上调至98港元，维持“买入/高风险”评级。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.